Sign In
The Challenge of Rare Disease Trials

The Challenge of Rare Disease Trials

Rare disease clinical trials present unique challenges that differ significantly from larger studies. With limited patient populations, protocols must often span multiple countries to recruit enough participants, creating a critical need for precise multilingual communication. Study materials such as consent forms, patient registries, and genetic test results require not only linguistic accuracy but also cultural adaptation to ensure comprehension across diverse communities.

In this high-stakes environment, a single mistranslation can delay recruitment, compromise data integrity, or result in regulatory setbacks for orphan drug designations and accelerated approval pathways. Sesen understands the complexities of rare disease trials and provides specialized translation workflows designed to support global recruitment, maintain compliance with agencies such as the FDA, EMA, and PMDA, and safeguard the success of small but vital studies.

Why Translation for Rare Disease Trials Requires Expertise

Rare disease studies demand a higher level of precision in translation than conventional clinical trials. Recruiting patients often requires reaching across multiple countries and languages, where every document must be linguistically accurate and culturally appropriate to avoid recruitment delays or protocol deviations.

The scientific content of these trials is highly specialized, covering areas such as genomics, gene therapy, and orphan drug development. Translators must be deeply familiar with emerging terminology and the evolving regulatory frameworks governing these therapies. Patient-facing materials add another layer of complexity, requiring sensitivity to cultural norms and health literacy levels to ensure informed consent and meaningful patient engagement.

Regulatory agencies apply heightened scrutiny to rare disease programs. Submissions linked to orphan drug status or accelerated pathways such as EMA PRIME or PMDA Sakigake require translations that meet the highest compliance standards. With Sesen, sponsors and CROs gain access to professional native linguists trained in rare disease contexts, supported by ISO-certified workflows that deliver accuracy, consistency, and regulatory confidence.

Read More Read Less

Rare Disease Trial Documents We Translate

Rare disease trials generate a wide range of specialized documents that must be translated with precision to support recruitment, data integrity, and regulatory compliance. Sesen provides expert translation for the following:

ICFs, brochures, outreach campaigns, and digital ads tailored for small and geographically dispersed patient populations, ensuring clear communication and ethical compliance.

Translation of longitudinal study documentation and registry data critical for understanding disease progression and supporting regulatory submissions.

Accurate translation of genetic reports, counseling guides, and laboratory findings to support patients, families, and healthcare providers in making informed decisions.

Specialized translations that align with rare disease study designs, covering investigational therapies such as gene therapy and biologics.

Translations that meet the strict formatting and terminology requirements of agencies such as the FDA, EMA, and PMDA for accelerated approval pathways.

Linguistic validation and back-translation of patient-reported outcome instruments to ensure reliability and comparability across multiple languages and regions.

Sesen’s Specialized Approach

Sesen combines deep subject matter expertise with advanced translation workflows tailored to the complexities of rare disease research. Our approach ensures accuracy, regulatory compliance, and cultural relevance across all trial documentation.

Our linguists are carefully selected for their backgrounds in genetics, molecular biology, and orphan drug development, bringing domain-specific knowledge to highly technical content.

Patient-reported outcomes, ePROs, and quality-of-life instruments require rigorous linguistic validation. Sesen applies standardized methodologies, including cognitive debriefing and back-translation, to guarantee reliability across small and diverse patient cohorts.

We leverage SesenGPT for terminology consistency and QA checks, paired with senior medical linguists who provide subject matter oversight. This hybrid workflow accelerates turnaround times without compromising precision or compliance.

All translation activities are conducted within HIPAA- and GDPR-compliant environments, with optional Single Sign-On (SSO) and encrypted file exchange to safeguard sensitive patient and trial data.

Sesen operates under ISO 17100 for translation services, ISO 13485 for medical devices, and ISO 9001:2015 for quality management. These certifications demonstrate our commitment to delivering audit-ready translations for regulatory submissions and global trial operations.

Case Example

Case Example

A leading biopharmaceutical company conducted a rare disease trial that required patient enrollment across more than a dozen countries. Recruitment depended on clear and culturally appropriate translations of consent forms, outreach materials, and patient diaries. Sesen assembled a team of professional native linguists with expertise in genetics and orphan drug studies to deliver validated translations in over 20 languages.

By applying linguistic validation workflows and leveraging SesenGPT for terminology consistency, we helped ensure that patient-facing content was accurate, compliant, and easily understood by families from diverse backgrounds. The trial successfully met enrollment targets within the projected timeline, supporting a critical orphan drug designation application.

Read the full case study here ›

Related Services

Rare disease trials intersect with multiple areas of life sciences where accurate and compliant translation is essential. Explore related Sesen services designed to support your global development programs:

  • Comprehensive support for all phases of clinical research, including study startup, patient-facing content, and regulatory documentation.
  • Specialized translation for adverse event reporting, safety updates, and regulatory submissions to ensure timely compliance in global markets.
  • Linguistic and cultural solutions to engage rare disease patients across diverse regions, improving enrollment and retention in small populations.
  • Expert translation for advanced therapies, including genetic testing reports, scientific publications, and regulatory filings in emerging therapeutic areas.

FAQs

Rare disease trials involve small and geographically dispersed patient populations, which means every translation must be precise to maximize recruitment and data integrity. These studies often focus on advanced therapies such as gene therapy or biologics and require compliance with orphan drug regulations. The translation process must therefore address complex scientific terminology while also meeting stricter regulatory scrutiny.

Patient-facing documents such as consent forms, recruitment brochures, and ePROs are adapted with sensitivity to local languages, literacy levels, and cultural norms. Sesen employs in-country linguists with life sciences expertise and applies structured cultural review workflows to ensure materials are both accurate and accessible to patients and their families.

Yes. Sesen offers linguistic validation and back-translation for patient-reported outcomes, quality-of-life questionnaires, and ePRO instruments. These services are essential in rare disease studies, where small sample sizes demand that every response be reliable and comparable across languages. Our workflows follow international best practices, including cognitive debriefing and harmonization.

Absolutely. We support global submissions for orphan drug designations and accelerated approval pathways such as FDA Orphan Drug, EMA PRIME, and PMDA Sakigake. Our translators and regulatory specialists ensure that all documentation is compliant, consistent, and audit-ready, enabling faster approvals across multiple regions.

Support Your Rare Disease Clinical Trials with Expert Translation

Partner with Sesen for specialized translation workflows that enable accurate patient communication, reliable data collection, and compliant regulatory submissions in rare disease research.

REQUEST A QUOTE REQUEST A QUOTE
CONTACT US CONTACT US